Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

41.01 +0.14 (+0.34%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna, Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
News headline image
Moderna Chief Technical Operations and Quality Officer Juan Andres Elected to National Academy of Engineering
CAMBRIDGE, MA / ACCESSWIRE / February 9, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Juan Andres, Chief... 
From Moderna, Inc.
Via AccessWire
News headline image
Moderna Announces New Supply Agreement with Colombia for Additional 10.8 Million Doses of Moderna's COVID-19 Vaccine
CAMBRIDGE, MA / ACCESSWIRE / February 8, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement... 
From Moderna, Inc.
Via AccessWire
News headline image
Moderna to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022
CAMBRIDGE, MA / ACCESSWIRE / February 3, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live... 
From Moderna, Inc.
Via AccessWire
News headline image
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax
Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose SPIKEVAX has received approval by regulators in more than 70... 
From Moderna, Inc.
Via AccessWire
News headline image
IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology
Phase 1 trial aims to build on response seen in proof-of-concept trial CAMBRIDGE, MA and NEW YORK, NY / ACCESSWIRE / January 27, 2022 / IAVI, the nonprofit scientific research organization, and... 
From Moderna, Inc.
Via AccessWire
News headline image
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant
Phase 2 study of Omicron-specific booster candidate (mRNA-1273.529) will include two cohorts: one including participants who received the two-dose primary series of mRNA-1273 and another including... 
From Moderna, Inc.
Via AccessWire
News headline image
Moderna Announces Advances Across Its Industry-Leading mRNA Pipeline and Provides Business Update
807 million doses of Moderna's COVID-19 vaccine shipped globally in 2021; approximately 25% of those doses shipped to low- and middle-income countries Product sales for 2021 approximately $17.5 billion... 
From Moderna, Inc.
Via AccessWire
News headline image
Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
Collaboration will combine Carisma's engineered macrophage technology with Moderna's mRNA and LNP technologies to generate and develop in vivo CAR-M therapeutics Multi-year research collaboration... 
From Moderna, Inc.
Via AccessWire
News headline image
Moderna Announces First Participant Dosed in Phase 1 Study of its mRNA Epstein-Barr Virus (EBV) Vaccine
Moderna expects to enroll approximately 270 participants in the U.S. EBV is a major cause of infectious mononucleosis, which can debilitate patients for weeks to months; there is no approved vaccine to... 
From Moderna, Inc.
Via AccessWire
News headline image
Moderna to Present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference
CAMBRIDGE, MA / ACCESSWIRE/ January 4, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel... 
From Moderna, Inc.
Via AccessWire
News headline image
Moderna to Provide Business and Pipeline Updates at the 2022 J.P. Morgan Healthcare Conference
CAMBRIDGE, MA / ACCESSWIRE / January 3, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel... 
From Moderna, Inc.
Via AccessWire
News headline image
Moderna Announces Supply Agreement with South Korea for Additional 20 Million Doses of Moderna’s COVID-19 Vaccine or Updated Booster Candidate in 2022
Agreement includes 15 million doses for delivery in the third quarter of 2022 and 5 million doses for delivery in the fourth quarter of 2022 CAMBRIDGE, MA / ACCESSWIRE / December 27, 2021 / Moderna,... 
From Moderna, Inc.
Via AccessWire
News headline image
Moderna Announces Switzerland Exercises its Option to Purchase Seven Million Additional Doses of Moderna's COVID-19 Booster Vaccine in 2022
Total of 27.5 million doses ordered by the Swiss Federal Government to date CAMBRIDGE, MA / ACCESSWIRE / December 27, 2021 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger... 
From Moderna, Inc.
Via AccessWire
News headline image
Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant
From Moderna, Inc.
Via Business Wire
News headline image
Moderna and Australia Announce Collaboration to Bring mRNA Manufacturing to Australia
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update
From Moderna, Inc.
Via Business Wire
News headline image
Moderna to Host Conference Call on Phase 1 Interim Analysis for mRNA Flu Vaccine on Friday, December 10
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Launches AI Academy in Partnership with Carnegie Mellon University
From Moderna, Inc.
Via Business Wire
Biotech Sector’s Response to Omicron Panic Should be Swift and Effective
FN Media Group Presents USA News Group News Commentary Vancouver, BC – December 7, 2021 – USA News Group – Despite a level of panic that JP Morgan has already downplayed in its 2022 forecasts, the... 
Via FinancialNewsMedia
News headline image
Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023
From Moderna, Inc.
Via Business Wire
News headline image
Moderna to Present at Upcoming Investor Conferences in December 2021
From Moderna, Inc.
Via Business Wire
News headline image
U.S. CDC Advisory Committee on Immunization Practices Recommends Booster Vaccination with Moderna’s COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces First Participant Dosed in Phase 2/3 Study of its mRNA Respiratory Syncytial Virus (RSV) Vaccine
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Tops BioSpace’s 2022 Best Places to Work Ranking in Large Employer Category
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Files for Authorization of its COVID-19 Vaccine with Health Canada to Include Children Ages 6-11 Years
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces European Union and European Economic Area Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to COVAX in 2021 to Help End COVID-19 Pandemic in Low Income Countries
From Moderna, Inc.
Via Business Wire
News headline image
Health Canada Authorizes Booster Dose of Moderna’s COVID-19 Vaccine in Individuals 18 Years of Age and Older
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces Positive Data from Phase 2 Study of mRNA VEGF-A Therapeutic in Patients Undergoing Coronary Artery Bypass Grafting Surgery
From Moderna, Inc.
Via Business Wire
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.